About your Search

20120901
20120930
Search Results 0 to 3 of about 4 (some duplicates have been removed)
transplants here in the united states. even with a transplant, the hepatitis will go right on attacking the new liver. this is a huge disease. it afflicts 170 million people around the world. which from a human perspective is just terrible, tragic. from a business perspective, these companies are involved. hep c can be a $20 million market opportunity. it's too darn good for many drug companies to pass up. now, i've talked about the game-changing new drugs developed for hep c on the show. but in recent months, there's been a reshuffling, major changes in the competitive race. i've got to keep you up on it. that's why tonight, i want to keep this opportunity in front of you and let you know who will benefit the most from the reshuffling of the order, the changes that have gone on and who can be the winners here. there are a lot of horses in this race. there was bristol-myers, abbott labs, gilead, merck, johnson & johnson, aventis. six months ago bristol-myers was in the definite lead. but one of the patients taking their hep c drug in the clinical trial had a heart attack. and the compan
Search Results 0 to 3 of about 4 (some duplicates have been removed)